MX2009000659A - Composiciones de polipeptidos de retrovirus endogeno humano y metodo para su uso. - Google Patents

Composiciones de polipeptidos de retrovirus endogeno humano y metodo para su uso.

Info

Publication number
MX2009000659A
MX2009000659A MX2009000659A MX2009000659A MX2009000659A MX 2009000659 A MX2009000659 A MX 2009000659A MX 2009000659 A MX2009000659 A MX 2009000659A MX 2009000659 A MX2009000659 A MX 2009000659A MX 2009000659 A MX2009000659 A MX 2009000659A
Authority
MX
Mexico
Prior art keywords
methods
present
herv
immune response
immunogenic compositions
Prior art date
Application number
MX2009000659A
Other languages
English (en)
Inventor
Mario Ostrowski
R Bradley Jones
Seth Rakoff-Nahoum
Douglas Nixon
Keith Garrison
Duncan Meiklejohn
Ashish Agrawal
Jack Lenz
Frederick M Hecht
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of MX2009000659A publication Critical patent/MX2009000659A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

La presente invención proporciona polipéptidos de HERV aislados, y composiciones que contienen un polipéptido de HERV. La presente invención proporciona composiciones inmunógenas que contienen un ácido nucleico que incluye una secuencia de nucleótidos que codifica un polipéptido de HERV. Las composiciones inmunógenas son útiles para estimular una respuesta inmunitaria en una célula T a un péptido lentiviral. La presente invención también proporciona métodos para tratar cánceres en los cuales se expresan polipéptidos de HERV. También se proporcionan métodos para tratar trastornos que involucran la disminución de una respuesta inmunitaria a un polipéptido HERV.
MX2009000659A 2006-07-21 2007-07-19 Composiciones de polipeptidos de retrovirus endogeno humano y metodo para su uso. MX2009000659A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83246506P 2006-07-21 2006-07-21
PCT/US2007/016403 WO2008011120A2 (en) 2006-07-21 2007-07-19 Human endogenous retrovirus polypeptide compositions and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2009000659A true MX2009000659A (es) 2009-06-08

Family

ID=38957380

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009000659A MX2009000659A (es) 2006-07-21 2007-07-19 Composiciones de polipeptidos de retrovirus endogeno humano y metodo para su uso.

Country Status (15)

Country Link
US (2) US20080171061A1 (es)
EP (1) EP2046380A4 (es)
JP (1) JP2009544614A (es)
KR (1) KR20090060410A (es)
CN (1) CN101557823A (es)
AU (1) AU2007275693A1 (es)
BR (1) BRPI0714714A2 (es)
CA (1) CA2658393A1 (es)
IL (1) IL196516A0 (es)
MX (1) MX2009000659A (es)
NO (1) NO20090818L (es)
RU (1) RU2009106089A (es)
SG (1) SG173997A1 (es)
WO (1) WO2008011120A2 (es)
ZA (1) ZA200900379B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20110072A1 (es) 2005-06-27 2011-02-04 Glaxosmithkline Biolog Sa Composicion inmunogenica
US20090297530A1 (en) 2006-05-22 2009-12-03 Feng Wang-Johanning Herv-k antigens, antibodies, and methods
EP2340851A4 (en) * 2008-09-18 2012-09-26 Univ Keio DIAGNOSTIC METHOD AND THERAPEUTIC METHOD FOR CANCER
US20110250218A1 (en) * 2008-10-29 2011-10-13 Fong Lawrence H Disease-Associated Antigens and Methods of Use Thereof
US20130028933A1 (en) * 2009-12-28 2013-01-31 Ligocyte Pharmaceuticals, Inc. Methods for stabilizing influenza antigen enveloped virus-based virus-like particle solutions
US20120321637A1 (en) * 2011-06-20 2012-12-20 The Board Of Regents Of The University Of Texas System Combination cancer therapy with herv inhibition
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
KR102317399B1 (ko) 2012-01-26 2021-10-26 반다 파마슈티칼즈, 인코퍼레이티드. 일주기 리듬 장애의 치료
WO2014153114A1 (en) * 2013-03-14 2014-09-25 Fred Hutchinson Cancer Research Center Compositions and methods to modify cells for therapeutic objectives
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
US10188749B2 (en) 2016-04-14 2019-01-29 Fred Hutchinson Cancer Research Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
JP7046016B2 (ja) * 2016-06-30 2022-04-01 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ Ｈｅｒｖ－ｅ反応性ｔ細胞受容体および使用方法
JP2019528071A (ja) * 2016-08-23 2019-10-10 エイムヴィオン・アクティエセルスカブＡｉｍＶｉｏｎ Ａ／Ｓ 新規免疫刺激ペプチド
JP7348063B2 (ja) 2017-01-05 2023-09-20 フレッド ハッチンソン キャンサー センター ワクチン効力を改善するためのシステム及び方法
EP3606550A2 (en) * 2017-04-03 2020-02-12 Neon Therapeutics, Inc. Protein antigens and uses thereof
WO2019043127A1 (en) * 2017-09-01 2019-03-07 Inprother Aps VACCINE FOR USE IN PROPHYLAXIS AND / OR TREATMENT OF DISEASE
US11793867B2 (en) 2017-12-18 2023-10-24 Biontech Us Inc. Neoantigens and uses thereof
JP2021536479A (ja) * 2018-09-06 2021-12-27 サントル レオン ベラール 抗癌ワクチンのための共有腫瘍抗原としてのｈｅｒｖ−ｋ由来抗原

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030092145A1 (en) * 2000-08-24 2003-05-15 Vic Jira Viral vaccine composition, process, and methods of use
US20030162263A1 (en) * 2001-09-06 2003-08-28 Marc Dupuis Peptides derived from the superantigen (SAg) ENV protein of HERV-K18 and their use in obtaining SAG-inhibitory antibodies and in vaccination against SAG
AT411262B (de) * 2001-09-27 2003-11-25 Wolff Klaus Dr Humanes endogenes retrovirus
US20070037147A1 (en) * 2001-12-07 2007-02-15 Pablo Garcia Endogenous retrovirus polypeptides linked to oncogenic transformation
US20040096457A1 (en) * 2001-12-11 2004-05-20 Huber Brigitte T Treatment and prevention of ebv infection and ebv-associated disorders
EP1338606A1 (en) * 2002-02-22 2003-08-27 Magnus Von Knebel Doeberitz Nucleic Acid encoding an HERV-H polypeptide for diagnosing colorectal cancer
EP2516459A1 (en) * 2009-12-22 2012-10-31 Aarhus Universitet (University Of Aarhus) Bivalent molecules for hiv entry inhibition
US20120321637A1 (en) * 2011-06-20 2012-12-20 The Board Of Regents Of The University Of Texas System Combination cancer therapy with herv inhibition

Also Published As

Publication number Publication date
RU2009106089A (ru) 2010-08-27
BRPI0714714A2 (pt) 2013-04-09
CN101557823A (zh) 2009-10-14
AU2007275693A1 (en) 2008-01-24
SG173997A1 (en) 2011-09-29
ZA200900379B (en) 2010-08-25
WO2008011120A2 (en) 2008-01-24
US20130323279A1 (en) 2013-12-05
WO2008011120A3 (en) 2008-11-06
KR20090060410A (ko) 2009-06-12
CA2658393A1 (en) 2008-01-24
NO20090818L (no) 2009-04-17
EP2046380A2 (en) 2009-04-15
US20080171061A1 (en) 2008-07-17
IL196516A0 (en) 2011-08-01
EP2046380A4 (en) 2013-05-01
JP2009544614A (ja) 2009-12-17

Similar Documents

Publication Publication Date Title
MX2009000659A (es) Composiciones de polipeptidos de retrovirus endogeno humano y metodo para su uso.
MX2010003110A (es) Composiciones de polipeptido de elemento nuclear intercalado largo y metodos de uso de las mismas.
MX2011013183A (es) Polipeptidos de la hormona de crecimiento y metodos de preparacion y su uso.
WO2006103666A3 (en) Isolated bid polypeptides, polynucleotides encoding same and antibodies directed thereagainst and methods of using same for inducing cell cycle arrest or apoptosis
TW201129379A (en) Anti-Orai1 antigen binding proteins and uses thereof
MX2010005783A (es) Secuencias de aminoacidos dirigidas contra citoquinas heterodimericas y/o sus receptores y polipeptidos que comprenden las mismas.
EP2470559A4 (en) COAGULATION FACTOR IX COMPOSITIONS AND METHODS OF MAKING AND USING THEM
WO2010115998A3 (en) Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
WO2006089001A3 (en) Lentiviral vectors and their use
MY156286A (en) Human il-23 antigen binding proteins
NZ602943A (en) Modified binding proteins inhibiting the vegf-a receptor interaction
WO2008089053A3 (en) Gp100-specific t cell receptors and related materials and methods of use
WO2009147248A3 (en) Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
MX2011006804A (es) Proteinas de enlace al receptor cgrp humano.
UA100682C2 (ru) АНТИТЕЛО, КОТОРОЕ НЕЙТРАЛИЗУЕТ ЧЕЛОВЕЧЕСКИЙ ЦИТОМЕГАЛОВИРУС (hCMV), И ЕГО ПРИМЕНЕНИЕ
IN2012DN02981A (es)
TN2012000393A1 (en) Agonist dr5 binding polypeptides
WO2007034489A3 (en) Immunogenic fragments of t-cell receptor constant domains and peptides derived therefrom
UA100127C2 (ru) Пептид cdh3 и лекарственное средство, содержащее его
MX2009008270A (es) Polipeptido novedoso que tiene actividad anti-tumoral.
MX2011008763A (es) Peptidos foxm1 y vacunas que contienen los mismos.
NZ706884A (en) Fc gamma receptor iib variants
MX2009007261A (es) Vacuna de peptido foxp3.
MX2010009071A (es) Peptidos aislados que tienen actividad inhibitoria de fosfolipasa.
PL1951283T3 (pl) Kompozycje farmaceutyczne do leczenia i zapobiegania rakowi jajnika

Legal Events

Date Code Title Description
FA Abandonment or withdrawal